A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemo
about
Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.Chronic Kidney Disease-Mineral and Bone Disorder in Asia.Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
P2860
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemo
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A phase 3, multicentre, random ...... rathyroidism in Japanese haemo
@en
A phase 3, multicentre, random ...... rathyroidism in Japanese haemo
@nl
type
label
A phase 3, multicentre, random ...... rathyroidism in Japanese haemo
@en
A phase 3, multicentre, random ...... rathyroidism in Japanese haemo
@nl
prefLabel
A phase 3, multicentre, random ...... rathyroidism in Japanese haemo
@en
A phase 3, multicentre, random ...... rathyroidism in Japanese haemo
@nl
P2093
P2860
P921
P356
P1476
A phase 3, multicentre, random ...... apanese haemodialysis patients
@en
P2093
Akifumi Fujii
Keitaro Yokoyama
Motoi Odani
ONO-5163 Study Group
Tadao Akizawa
Takashi Akiba
Takashi Shigematsu
Takuto Kuramoto
P2860
P304
P356
10.1093/NDT/GFW408
P407
P577
2017-10-01T00:00:00Z